Q-omics provides the consensus-scored TCF20 profile across patient tissues and cancer cell-line models. TCF20 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TCF20 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TCF20 protein abundance shows 25,291 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where TCF20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF20 survival associations across molecular data types. TCF20 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF20 RNA expression–survival associations across cancer types. High TCF20 expression shows unfavorable associations in ACC, LIHC and PAAD, but favorable associations in KIRC, SCLC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TCF20 RNA expression.
This table summarizes TCF20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TCF20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF20 shows higher tumor expression in HNSC, BLCA, LIHC, COAD, LUSC and STAD. The HNSC box plot shows higher TCF20 RNA expression in tumor versus normal tissue (log2 FC = +1.087, t-test p < 0.001).
This table shows molecular features associated with TCF20 in patient tissues and cancer cell lines. In patient samples, TCF20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
